Abstract: A single atom catalyst and a method of forming the same are provided. The single atom catalyst comprises a support comprising a first metal oxide and a second metal atom located in the first metal oxide. The method of forming the single atom catalyst comprises forming a sacrificial nanoparticle, coating the sacrificial nanoparticle with a first metal oxide, adsorbing a second metal atom to the first metal oxide, forming a sacrificial layer on the support, and heating the first metal oxide.

Abstract: Provided is a preparing method of linear carbonate compounds, including performing a coupling reaction of carbon dioxide in the presence of a titanium dioxide complex. The titanium dioxide complex includes an anatase phase and a rutile phase, a reduced titanium dioxide which is formed by selectively reducing any one of the anatase phase and the rutile phase, and a metallic oxide bound to the reduced titanium dioxide.

Abstract: The present application relates to an electrode catalyst for water electrolysis including a first transition metal foam, a metal layered double hydroxide (LDH)/metal oxide mixed layer which contains a second transition metal and a third transition metal that are formed on the surface of the first transition metal foam, and fourth transition metal oxyhydroxide nanoparticles formed on the surface of the mixed layer, in which the mixed layer surface contains the metal layered double hydroxide.

Abstract: Provided is a probe system for low-temperature high-precision heat transport measurement, the probe system including a sample loader where a sample is loaded. In the probe system for low-temperature high-precision heat transport measurement, the sample loader includes a first frame including a sample loading space, and a second frame including an open end coupled to the first frame to accommodate the sample loading space.

Abstract: Embodiments of the present disclosure may include a key generation device of a lattice-based public key cryptosystem. In some embodiments, the key generation device may include a communication unit, a storage unit, and a processor that may be configured to control the key generation device to perform operations. In some embodiments, the operations may include generating a public key by using a public key polynomial, where the public key polynomial may belong to a first polynomial ring. In some embodiments, the operations may additionally include generating a secret key that may correspond to the public key. In some embodiments, the secret key may be generated by using a secret key polynomial that may belong to a second polynomial ring. In some embodiments, the operations may additionally include storing the public key and the secret key.

Abstract: The present invention refers to an antibody against Tie-2 or antigen-binding fragment thereof, a nucleic acid encoding the same, a vector comprising the nucleic acid, a cell transformed with the vector, a manufacturing method of the antibody or antigen-binding fragment thereof, and a composition for preventing or treating angiogenic diseases, which comprises the antibody or antigen-binding fragment thereof.

Abstract: A method of forming a compound structure according to embodiments of the present disclosure comprises loading a metal precursor on a substrate, providing a chalcogen precursor to the substrate, and reacting the chalcogen precursor with the metal precursor. The metal precursor comprises transition metal nanoparticles. The compound structure has a 2-dimensional structure.

Abstract: The present invention relates to the preparation of an antibody analogue capable of being activated reversibly, and uses thereof, and provides a fusion protein comprising an inactive first fragment of an antibody analogue is fused to a stimulus-induced dimerization protein.

Abstract: Disclosed is an image analysis system which includes a first analyzer and a second analyzer. The first analyzer generates first features by encoding images through a first model and adjusts a weight of the first model based on the first features. The second analyzer generates second features based on the first features by encoding the images through a second model, classifies the second features into classes, respectively, and adjusts a weight of the second model based on mutual information and a correlation between a first class among the classes which features corresponding to an original image group from among the second features are classified as and a second class among the classes which features corresponding to an augmentation group of the original image group from among the second features are classified as.

Abstract: The present invention relates to a yeast-derived polysaccharide inducing Treg cells and a use thereof and, more particularly, to a polysaccharide comprising mannan and ?-glucan, an composition for immunomodulation comprising the polysaccharide as an active ingredient, a pharmaceutical composition or food comprising the polysaccharide as an active ingredient for prevention or treatment of immune disease or inflammatory disease, a method for preparation of regulatory T cells by using the polysaccharide, a cell therapeutic agent comprising the regulatory T cells prepared by the preparation method as an active ingredient, and a treatment method using same.

Abstract: The present invention relates to a preparation method for pyrimidine-2-amine and, more specifically, to a method for preparing a pyrimidine-2-amine compound via a pyrimidine-2-iminium salt intermediate by using a nucleophilic imine-type reagent, in which various amino functional groups are selectively introduced at position No. 2 of pyrimidine.

Abstract: Provided is a CRY2 variant in which E279 and/or E281 having a negative charge in a N277SEGE281 sequence of SEQ ID NO: 1 is substituted with any one selected from the neutral amino acid group of alanine (A), isoleucine (I), leucine (L), valine (V), phenylalanine (F), methionine (M) and tryptophan (W), or in which S278 or G280 of a N277SEGE281 sequence of SEQ ID NO: 1 is substituted with any one selected from the bulky amino acid group of tryptophan (W) and phenylalanine (F).

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating attention deficit/hyperactivity disorder (ADHD), including SNAP5114 as an active ingredient. A Git1 gene-deficient hetero (+/?) mouse, confirmed to have increased amount of GABA in the brain striatum that controls hyperactivity, can be used as an animal model of ADHD, and by confirming that hyperactivity is ameliorated by administering SNAP5114 to the Git1 gene-deficient hetero (+/?) mouse, SNAP5114 is provided as a therapeutic agent for ADHD.

Abstract: An electronic device included in a cryptosystem is disclosed. The electronic device comprising a communication device configured to communicate data, a memory configured to store a cryptographic program and a processor configured to control the electronic device to performs operations by executing the cryptographic program, wherein the operations include, receiving a public key of another electronic device from the another electronic device included in the cryptosystem, generating an electronic signature for the public key of the another electronic device and generating a public key certificate including the public key of the another electronic device, and the electronic signature, wherein the cryptographic program of the electronic device is a program applied to a cryptographic algorithm safe against to an attack based on a quantum computer.

Abstract: The present invention relates to a nano-vesicle reactor and a method for producing the same. Specifically, the present invention provides a composition for producing a nano-vesicle reactor, characterized by comprising a first vesicle containing a first receptor on its surface and a second vesicle containing a second receptor on its surface, wherein the first receptor and the second receptor are bound with each other through a ligand system so that the first vesicle and the second vesicle are fused to form the nano-vesicle reactor; and a method for producing the above nano-vesicle reactor. The nano-vesicle reactor of the present invention can be utilized in production of energy inside a cell through cellular enzymatic reaction, a drug delivered system, and a diagnostic system.

Abstract: A focus scan type imaging device for imaging a target object in a sample that induces aberration proposed. The device includes: a light source unit for emitting a beam; an optical interferometer for splitting the beam emitted from the light source into a sample wave and a reference wave, and providing an interference wave formed by interference between a reflection wave that is the sample wave reflected from the sample and the reference wave; a camera module for imaging the interference wave; a scanning mirror disposed on an optical path of the sample wave of the optical interferometer and configured to reflect the sample wave to cause the sample wave to scan the sample; a wavefront shaping modulator disposed on the optical path of the sample wave of the optical interferometer; and an imaging controller configured to operate in a phase map calculation mode and in an imaging mode.

Abstract: Provided is a preparing method of an amide directly from a tertiary amine by using a reduced titanium dioxide (Blue TiO2), which is formed by mixing a titanium dioxide having an anatase phase and a rutile phase with a reducing agent and selectively reducing any one of the anatase phase and the rutile phase, as a photocatalyst.

Abstract: The present invention refers to an antibody against Tie-2 or antigen-binding fragment thereof, a nucleic acid encoding the same, a vector comprising the nucleic acid, a cell transformed with the vector, a manufacturing method of the antibody or antigen-binding fragment thereof, and a composition for preventing or treating angiogenic diseases, which comprises the antibody or antigen-binding fragment thereof.

Abstract: Described herein is a method of preventing or treating a neurodegenerative disease including administering an agent to a person in which the agent causes increase in outflow of cerebrospinal fluid through nasopharyngeal lymphatic plexus (NPLP), or an agent that causes contraction and relaxation of the circular smooth muscles covering the deep cervical lymphatic vessels (dcLVs).

Abstract: The present invention relates to an artificially manipulated neovascularization-associated factor for regulating neovascularization and a use thereof. More particularly, the present invention relates to a system for artificially regulating neovascularization, which includes an artificially manipulated neovascularization-associated factor for regulating neovascularization and/or a composition for artificially manipulating the neovascularization-associated factor. In a specific aspect, a neovascularization regulatory system including a neovascularization-associated factor such as artificially manipulated VEGFA, HIF1A, ANGPT2, EPAS1, or ANGPTL4 and/or an expression product thereof is provided.